LUND, SWEDEN -- (MARKET WIRE) -- September 05, 2006 -- The once-daily novel oral agent for relapsing remitting multiple sclerosis (MS) patients met its primary endpoint
LUND, SWEDEN -- (MARKET WIRE) -- September 05, 2006 -- The once-daily novel oral agent for relapsing remitting multiple sclerosis (MS) patients met its primary endpoint